Apexigen is a clinical-stage biopharmaceutical company focusing on the discoveryand development of innovative antibody-based therapeutics for the treatment of cancerwith a focus on immuno-oncology. The companys pipeline of immuno-oncology therapeuticcandidates is led by sotigalimab, which is currently in clinical development, andalso includes several preclinical stage immune-oncology programs.
Apexigens APXiMAB technology platform enablesApexigen and its partners to discover high-quality antibody drug candidates againstchallenging disease targets. Apexigen has established multiple corporate partnerships:five of these partners are conducting clinical trials of antibodies discovered throughthe use of the APXiMAB platform.